TOKYO, Mar 31 (Pulse News Wire) – GNI Group Ltd. (2160.T) reported record revenue for fiscal year 2025, achieving a year-over-year increase of approximately ¥3 billion.
The pharmaceutical and medical technology segments drove growth, contributing to past highest sales figures. Operating profit reached ¥1.274 billion, up from ¥942 million in the previous year. In its latest financial report, GNI highlighted key performance indicators aimed at increasing revenues by 20-40% and managing research and development costs within 20% of total revenue.
The company also noted significant progress in clinical trials, including positive results from the Phase III trial of drug candidate F351, which has completed its new drug application submission. Looking ahead, GNI forecasts continued expansion in its medical tech segment and strategic investments in development compounds such as F528, F573, and F230. However, certain factors remain undetermined, including the timing and scope of future investments and regulatory approvals impacting growth projections.
🟡 Confidence: Standard AI-translated content.